{"components":{"securitySchemes":{"BearerAuth":{"bearerFormat":"fw_live_<32 hex>","scheme":"bearer","type":"http"}}},"info":{"description":"Programmatic access to every Frontwind sidebar agent. Authenticate with `Authorization: Bearer fw_live_<your-key>`.","title":"Frontwind Agent API","version":"1.0.0"},"openapi":"3.1.0","paths":{"/v1/agents/alerts":{"post":{"description":"CRUD over the caller's alert subscriptions. Pass an ``action`` field to choose the operation.","operationId":"run_alerts","requestBody":{"content":{"application/json":{"example":{"action":"list"},"schema":{"properties":{"action":{"enum":["list","enable_from_query","remove","add_manual"],"type":"string"},"drug_name":{"description":"Required for add_manual.","type":"string"},"query_id":{"description":"Required for enable_from_query / remove.","type":"integer"},"signal_level":{"default":"medium","enum":["low","medium","high"],"type":"string"}},"required":["action"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"alerts","data":{"action":"list","queries":[{"alerts_enabled":true,"id":9421,"query":"TROP2 ADC"}],"quota":{"at_cap":false,"enabled_count":3,"max_enabled":10}},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"action":{"type":"string"},"queries":{"type":"array"},"quota":{"type":"object"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"List / enable / disable / add saved competitive-intel alerts.","tags":["alerts"]}},"/v1/agents/assay-development":{"post":{"description":"Builds a structured assay development package for a therapeutic program, including assay categories, formats, reasoning traces, protocol skeletons, validation/QC strategy, risks, and sources.","operationId":"run_assay_development","requestBody":{"content":{"application/json":{"example":{"assay_goal":"IND_enabling","development_stage":"preclinical","include_protocol_skeletons":true,"include_qc_release":true,"indication":"relapsed/refractory multiple myeloma","mechanism":"Autologous BCMA CAR-T intended to kill BCMA-positive myeloma cells","modality":"CAR-T","product_details":{"cell_source":"autologous T cells","construct":"second-generation CAR with 4-1BB costimulatory domain"},"sample_context":{"models_available":["BCMA+ myeloma cell lines","primary myeloma samples","NSG xenograft"]},"target":"BCMA"},"schema":{"properties":{"assay_goal":{"description":"Primary assay package goal.","enum":["candidate_selection","mechanism_of_action","potency","CMC_release","IND_enabling","translational_biomarkers"],"type":"string"},"constraints":{"type":"object"},"development_stage":{"default":"preclinical","enum":["discovery","lead_optimization","preclinical","IND_enabling","phase1","phase2","phase3","commercial"],"type":"string"},"include_protocol_skeletons":{"default":true,"type":"boolean"},"include_qc_release":{"default":true,"type":"boolean"},"indication":{"description":"Disease or experimental context.","type":"string"},"mechanism":{"description":"Therapeutic hypothesis or MoA.","type":"string"},"modality":{"description":"Therapeutic modality. Website uses the same enum as a dropdown.","enum":["CAR-T","TCR-T","TIL therapy","NK cell therapy","T cell engager","antibody","ADC","small molecule","protein biologic","gene therapy","RNA therapy","vaccine","other"],"type":"string"},"product_details":{"type":"object"},"requested_categories":{"items":{"type":"string"},"type":"array"},"sample_context":{"type":"object"},"target":{"description":"Molecular/cellular target.","type":"string"},"uploaded_files":{"description":"File IDs returned by the website upload route.","items":{"type":"string"},"type":"array"},"use_cache":{"default":false,"type":"boolean"}},"required":["modality","indication","assay_goal"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"assay-development","data":{"assay_strategy":"BCMA CAR-T potency should combine antigen-specific killing with kinetic, cytokine, and phenotype readouts.","executive_summary":"Use a staged potency package centered on kinetic killing, cytokine release, activation, repeat-kill persistence, and release-ready identity/potency assays.","protocol_skeletons":[],"qc_release_strategy":{},"recommended_assay_package":[{"category":"cytotoxicity_killing","formats":[{"controls":["BCMA-negative target cells","mock T cells"],"name":"IncuCyte live imaging","priority":"High","readouts":["target cell death over time","E:T sensitivity"],"reasoning_trace":["target expression may be heterogeneous","kinetic readout preferred","serial killing behavior matters for CAR-T","recommend live imaging assay"],"stage":"Preclinical"}],"rationale":"Primary functional potency signal for BCMA-positive target cells."}],"validation_plan":{},"warnings":[]},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"assay_strategy":{"type":"string"},"context_used":{"items":{"type":"object"},"type":"array"},"controls_and_reagents":{"items":{"type":"object"},"type":"array"},"decision_framework":{"type":"object"},"evidence":{"items":{"type":"object"},"type":"array"},"executive_summary":{"type":"string"},"input":{"type":"object"},"model_systems":{"items":{"type":"object"},"type":"array"},"protocol_skeletons":{"items":{"type":"object"},"type":"array"},"qc_release_strategy":{"type":"object"},"query_id":{"type":"integer"},"recommended_assay_package":{"items":{"properties":{"category":{"type":"string"},"formats":{"items":{"properties":{"controls":{"items":{"type":"string"},"type":"array"},"name":{"type":"string"},"priority":{"type":"string"},"readouts":{"items":{"type":"string"},"type":"array"},"reasoning_trace":{"items":{"type":"string"},"type":"array"},"stage":{"type":"string"}},"type":"object"},"type":"array"},"rationale":{"type":"string"}},"type":"object"},"type":"array"},"risks_and_mitigations":{"items":{"type":"object"},"type":"array"},"run_uuid":{"type":"string"},"sources":{"items":{"type":"object"},"type":"array"},"status":{"type":"string"},"timeline":{"items":{"type":"object"},"type":"array"},"validation_plan":{"type":"object"},"warnings":{"items":{"type":"string"},"type":"array"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Design a modality-aware assay development and validation plan.","tags":["assay-development"]}},"/v1/agents/attribution-engine":{"post":{"description":"Consumes daily stock returns, a biotech-sector benchmark return series such as XBI, and event records from catalyst, financing, and IP agents. It emits confirmed, read-through, partial, and unexplained attribution states, including leakage checks and a magnitude floor so statistically significant but immaterial moves do not flood the signal feed.","operationId":"run_attribution_engine","requestBody":{"content":{"application/json":{"example":{"benchmark":"XBI","events":[{"asset":"NVX-101","confirmed":true,"date":"2026-05-04","event_type":"PDUFA date set","expected_abs_move":0.18,"relationship":"own","source":"EDGAR 8-K"}],"returns":[{"date":"2026-05-01","market":0.003,"stock":0.01},{"date":"2026-05-04","market":0.004,"stock":0.06}]},"schema":{"properties":{"benchmark":{"default":"XBI","type":"string"},"config":{"type":"object"},"events":{"description":"Rows with date, asset, event_type, relationship, confirmed, and expected_abs_move.","type":"array"},"returns":{"description":"Rows with date, stock, and market daily simple returns.","type":"array"},"unexplained_window":{"default":5,"type":"integer"}},"required":["returns","events"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"attribution-engine","data":{"attributions":[{"car":0.45,"leakage_flag":false,"move_date":"2026-05-04","note":"realized 45% exceeds expected 18%; residual 27% unexplained by this event","residual":0.27,"scar":9.0,"state":"partial"}],"benchmark":"XBI","config":{"min_abs_move":0.08,"sig_z":1.96},"method":"sector beta-adjusted market model with expected-move residual and economic magnitude floor","unexplained":[]},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"attributions":{"items":{"type":"object"},"type":"array"},"benchmark":{"type":"string"},"config":{"type":"object"},"method":{"type":"string"},"unexplained":{"items":{"type":"object"},"type":"array"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Classify beta-adjusted stock moves around biotech events.","tags":["attribution-engine"]}},"/v1/agents/clinical-trial-design":{"post":{"description":"Builds a structured clinical trial design report for a drug asset and indication, including recommended design, schema, target population, endpoint and comparator strategy, statistical design recommendations, safety monitoring, operational feasibility, competitive benchmarking, regulatory risks, and next steps.","operationId":"run_clinical_trial_design","requestBody":{"content":{"application/json":{"example":{"asset_name":"FW-201","competitor_trials":["MajesTEC-1","MagnetisMM-3","KarMMa"],"development_stage":"Phase 2","geography":"FDA","indication":"relapsed/refractory multiple myeloma","line_of_therapy":"after at least three prior lines","mechanism_of_action":"BCMA x CD3 T-cell engagement","modality":"bispecific antibody","preferred_endpoint":"ORR with DoR","preliminary_efficacy_data":{"CR":"28%","ORR":"62%","median_DoR":"not reached"},"safety_profile":{"CRS":"55%","Grade3_Infections":"18%"},"target":"BCMA"},"schema":{"properties":{"asset_name":{"description":"Asset or program name.","type":"string"},"biomarker_strategy":{"type":"string"},"combination_partners":{"items":{"type":"string"},"type":"array"},"competitor_trials":{"items":{"type":"string"},"type":"array"},"development_stage":{"description":"Current development stage.","type":"string"},"dosing_schedule":{"type":"string"},"geography":{"description":"Regulatory geography, e.g. FDA, EMA, PMDA.","type":"string"},"indication":{"description":"Target disease and population.","type":"string"},"intended_label_claim":{"type":"string"},"line_of_therapy":{"type":"string"},"manufacturing_constraints":{"type":"object"},"mechanism_of_action":{"description":"Mechanism of action.","type":"string"},"modality":{"description":"Therapeutic modality.","type":"string"},"preferred_endpoint":{"type":"string"},"preliminary_efficacy_data":{"type":"object"},"regulatory_designations":{"items":{"type":"string"},"type":"array"},"route_of_administration":{"type":"string"},"safety_profile":{"type":"object"},"target":{"description":"Molecular or cellular target.","type":"string"},"target_patient_population":{"type":"string"},"use_cache":{"default":false,"type":"boolean"}},"required":["asset_name","indication","modality","mechanism_of_action","target","development_stage","geography"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"clinical-trial-design","data":{"competitive_trial_benchmarking":[{"asset":"teclistamab","comparator":"single-arm","endpoint":"ORR","outcome":"Supported approval precedent [1]","phase":"Phase 1/2","population":"RRMM after multiple prior lines","sample_size":"N/R","source_ids":["1"]}],"executive_summary":{"competitive_positioning_considerations":["Differentiate on response durability, outpatient feasibility, and safety management [1][2]."],"confidence":"Medium","confidence_score":65,"likely_regulatory_pathway":"Accelerated approval may be plausible if response durability and safety are compelling in a refractory population [1][2].","major_design_risks":["single-arm evidence dependency [1]","CRS/infection monitoring burden [2]"],"recommended_trial_strategy":"Base case is a single-arm Phase 2 in heavily pretreated RRMM with ORR and DoR as the registrational evidence package, paired with an early randomized confirmatory plan [1][2].","source_ids":["1","2"]},"recommended_trial_design":{"confidence":"Medium","confidence_score":65,"design_type":"Phase 2 single-arm with confirmatory randomized follow-on","precedent_support":["BCMA bispecific precedent","BCMA CAR-T precedent"],"rationale":"A refractory setting can support response-based development when randomized SOC is operationally difficult, but confirmatory evidence remains a key risk [1].","regulatory_feasibility":"Medium; depends on durability, safety database, and confirmatory plan [1][2].","source_ids":["1","2"]},"sources":[{"id":"1","relevance":"BCMA bispecific trial precedent","source_type":"FDA approval package","title":"TECVAYLI approval materials","url":"https://www.accessdata.fda.gov/"}],"warnings":["Design recommendations are strategic and not a final SAP or regulatory advice."]},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"assumptions":{"items":{"type":"string"},"type":"array"},"comparator_strategy":{"type":"object"},"competitive_trial_benchmarking":{"items":{"type":"object"},"type":"array"},"endpoint_strategy":{"items":{"type":"object"},"type":"array"},"executive_summary":{"type":"object"},"input":{"type":"object"},"operational_feasibility_analysis":{"type":"object"},"precedents":{"items":{"type":"object"},"type":"array"},"proposed_trial_schema":{"type":"object"},"query_id":{"type":"integer"},"recommended_next_steps":{"items":{"type":"object"},"type":"array"},"recommended_trial_design":{"type":"object"},"regulatory_risks":{"items":{"type":"object"},"type":"array"},"run_uuid":{"type":"string"},"safety_monitoring_recommendations":{"type":"object"},"sources":{"items":{"type":"object"},"type":"array"},"statistical_design_recommendations":{"type":"object"},"status":{"type":"string"},"strategy_scenarios":{"items":{"type":"object"},"type":"array"},"target_patient_population":{"type":"object"},"warnings":{"items":{"type":"string"},"type":"array"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Generate a precedent-backed clinical trial design strategy.","tags":["clinical-trial-design"]}},"/v1/agents/company-asset-searcher":{"post":{"description":"Checks Patsnap's drug database first, then uses Claude web search to resolve a biotech company's pipeline, including in-house, licensed-in, acquired, partnered, licensed-out, and divested assets. It explicitly traces assets across former entity names, originator codes, regional partners, alternative drug names, and ClinicalTrials.gov sponsor mismatches. Licensing evidence is prioritized from SEC material-contract exhibits and filings, then company IR/press releases, FDA Orange/Purple Book patent listings, Bayh-Dole academic/government IP trails, and litigation, bankruptcy, or M&A disclosures. Each asset includes a next-catalyst estimate with date confidence and a phase-by-therapeutic-area weight so Phase 1 oncology data, ordinary Phase 1 safety updates, pivotal readouts, regulatory events, conference windows, and China licensing deals do not collapse into the same flat stage list.","operationId":"run_company_asset_searcher","requestBody":{"content":{"application/json":{"example":{"company":"Arvinas","company_aliases":["Arvinas, Inc."],"max_searches":12,"model":"sonnet"},"schema":{"properties":{"company":{"description":"Company name or ticker to scan, e.g. 'Arvinas' or '\u4fe1\u8fbe\u751f\u7269'.","type":"string"},"company_aliases":{"description":"Optional known company aliases or legal names to check in Patsnap first.","type":"array"},"max_searches":{"default":12,"description":"Maximum server-side Claude web searches for the scan.","maximum":25,"minimum":1,"type":"integer"},"model":{"default":"sonnet","description":"Claude model family. Use opus for higher-accuracy diligence runs.","enum":["sonnet","opus","haiku"],"type":"string"},"patsnap_limit":{"default":60,"description":"Maximum Patsnap database assets to seed before web search.","maximum":150,"minimum":1,"type":"integer"}},"required":["company"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"company-asset-searcher","data":{"asOf":"latest public sources","company":"Arvinas, Inc.","drugs":[{"aliases":["ARV-471"],"code":"ARV-471","indication":"ER+/HER2- breast cancer","modality":"PROTAC degrader","name":"vepdegestrant","next_catalyst":{"category":"Data","date":"TBD","date_confidence":"tbd","event":"Pivotal topline readout","rationale":"Pivotal data is the highest pre-approval de-risking event.","source":"patsnap+web_search","weight":"very_high","weight_score":90},"note":"Co-developed with Pfizer; pivotal breast-cancer studies may reference both sponsor names.","origin":"partnered","partner":"Pfizer","phase":"Phase 3","source":"patsnap+web_search","target":"estrogen receptor"}],"generated_at":"2026-05-28T00:00:00+00:00","model":"claude-sonnet-4-6","patsnap":{"company_aliases_checked":["Arvinas","Arvinas, Inc."],"count":1,"first":true,"message":"Patsnap organization lookup completed.","status":"completed"},"summary":"Arvinas is centered on clinical-stage targeted protein degradation assets.","ticker":"NASDAQ:ARVN","usage":{"web_search_requests":8},"web_search":{"message":"Claude web search reconciled Patsnap seeds against public sources.","status":"completed"}},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"asOf":{"type":"string"},"company":{"type":"string"},"drugs":{"items":{"properties":{"aliases":{"type":"array"},"code":{"type":["string","null"]},"indication":{"type":["string","null"]},"modality":{"type":["string","null"]},"name":{"type":"string"},"next_catalyst":{"properties":{"category":{"enum":["Data","Regulatory","Conference","BD / licensing","IND / timing","Commercial","None","Unknown"],"type":"string"},"date":{"type":"string"},"date_confidence":{"enum":["confirmed","estimated","window","tbd"],"type":"string"},"event":{"type":"string"},"rationale":{"type":"string"},"source":{"type":["string","null"]},"weight":{"enum":["very_high","high","medium","low","timing_only","none"],"type":"string"},"weight_score":{"maximum":100,"minimum":0,"type":"integer"}},"type":"object"},"note":{"type":["string","null"]},"origin":{"enum":["in-house","licensed-in","acquired","licensed-out","partnered",null],"type":["string","null"]},"partner":{"type":["string","null"]},"phase":{"enum":["Approved","Filed","Phase 3","Phase 2","Phase 1","Preclinical","Discontinued","Unknown"],"type":"string"},"source":{"type":["string","null"]},"target":{"type":["string","null"]}},"type":"object"},"type":"array"},"generated_at":{"type":"string"},"model":{"type":"string"},"patsnap":{"properties":{"company_aliases_checked":{"type":"array"},"count":{"type":"integer"},"first":{"type":"boolean"},"message":{"type":"string"},"status":{"type":"string"}},"type":"object"},"summary":{"type":"string"},"ticker":{"type":["string","null"]},"usage":{"type":"object"},"web_search":{"properties":{"message":{"type":"string"},"status":{"type":"string"}},"type":"object"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Map every public drug asset associated with a company.","tags":["company-asset-searcher"]}},"/v1/agents/competitive-landscaping":{"post":{"description":"Searches AACT, Chinese registries, Google Scholar, and patent sources for drugs matching the query, ranks them by mechanism / phase / competitive density, and returns the structured drug table.","operationId":"run_competitive_landscaping","requestBody":{"content":{"application/json":{"example":{"candidate_asset_description":"Series A TROP2 ADC from ExampleBio; Phase 1 in NSCLC; differentiated linker-payload.","include_patents":false,"indication":"NSCLC","query":"TROP2 ADC in NSCLC","query_type":"both","skip_drug_cache":false,"use_cache":false},"schema":{"properties":{"candidate_asset_description":{"description":"Optional description of the asset under diligence (company, modality, stage, differentiation). Used in the VC-style pipeline summary memo.","type":"string"},"include_aact":{"default":true,"type":"boolean"},"include_chictr":{"default":false,"type":"boolean"},"include_chinese":{"default":true,"type":"boolean"},"include_conferences":{"default":true,"type":"boolean"},"include_exa":{"default":true,"type":"boolean"},"include_google_open":{"default":true,"type":"boolean"},"include_llm_web_search":{"default":true,"type":"boolean"},"include_patents":{"default":false,"type":"boolean"},"indication":{"description":"Optional indication constraint to pass directly into the pipeline.","type":"string"},"query":{"description":"Natural-language query, e.g. 'TROP2 ADC in NSCLC'.","type":"string"},"query_type":{"default":"preclinical","description":"Both modes return the same drug-table shape via drugs[]. preclinical focuses on discovery/preclinical-stage assets; clinical biases discovery toward drugs with active trials. both runs clinical and preclinical searches in parallel and returns a merged drug table with per-mode run metadata. Drug rows include synthesized efficacy and toxicity fields when evidence is available.","enum":["preclinical","clinical","both"],"type":"string"},"skip_drug_cache":{"default":false,"description":"Skip drug_indication_cache reads/injection (Phase 6.0) and Phase 6.2 cache-skip for all-cached article sources. Forces fresh GPT verify+enrich.","type":"boolean"},"use_cache":{"default":false,"description":"Use cached Competitive Landscaping results when available for the same query.","type":"boolean"}},"required":["query"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"competitive-landscaping","data":{"drugs":[{"company":"Daiichi Sankyo / AstraZeneca","drug_name":"Datopotamab deruxtecan","efficacy":"Reported objective response and survival endpoints in TROP2 ADC trials.","indication":"NSCLC","modality":"ADC","stage":"PHASE3","target":"TROP2","toxicity":"Common treatment-emergent adverse events include stomatitis and nausea."}],"indication_specific_results":{"biomarkers":[],"clinical_endpoints":[],"indication":"NSCLC","patient_subsets":[],"sources":[],"warnings":[]},"input_tokens":1450000,"output_tokens":50000,"pipeline_summary":"## Executive summary\n\nThe TROP2 ADC landscape in NSCLC is crowded...","query":"TROP2 ADC in NSCLC","query_id":9421,"query_type":"both","relevance_criteria":{"clinical":"Clinical drug must be an ADC that targets TROP2 and is being developed or used for NSCLC.","preclinical":"Preclinical drug must be an ADC that targets TROP2 and is being developed for NSCLC."},"relevance_criterion":"Drug must be an ADC that targets TROP2 and is being developed or used for NSCLC.","run_id":"abc-123","run_uuid":"f1a4...","runs":{"clinical":{"drug_count":3,"input_tokens":810000,"output_tokens":32000,"run_id":"abc-123-clinical","total_tokens":842000},"preclinical":{"drug_count":2,"input_tokens":640000,"output_tokens":18000,"run_id":"abc-123-preclinical","total_tokens":658000}},"total_tokens":1500000,"usage":{"by_mode":{"clinical":{"input_tokens":810000,"output_tokens":32000,"total_tokens":842000},"preclinical":{"input_tokens":640000,"output_tokens":18000,"total_tokens":658000}},"openai":{"calls":780,"input_tokens":1450000,"output_tokens":50000,"total_tokens":1500000},"pipeline":"competitive_landscaping","schema_version":2}},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"drugs":{"items":{"properties":{"company":{"type":"string"},"drug_name":{"type":"string"},"efficacy":{"type":"string"},"indication":{"type":"string"},"modality":{"type":"string"},"stage":{"type":"string"},"target":{"type":"string"},"toxicity":{"type":"string"}},"type":"object"},"type":"array"},"indication_specific_results":{"properties":{"biomarkers":{"items":{"type":"object"},"type":"array"},"clinical_endpoints":{"items":{"type":"object"},"type":"array"},"indication":{"type":"string"},"patient_subsets":{"items":{"type":"object"},"type":"array"},"sources":{"items":{"type":"object"},"type":"array"},"warnings":{"items":{"type":"string"},"type":"array"}},"type":"object"},"input_tokens":{"type":"integer"},"output_tokens":{"type":"integer"},"pipeline_summary":{"type":"string"},"query":{"type":"string"},"query_id":{"type":"integer"},"query_type":{"type":"string"},"relevance_criteria":{"type":"object"},"relevance_criterion":{"type":"string"},"run_id":{"type":"string"},"run_uuid":{"type":"string"},"runs":{"type":"object"},"total_tokens":{"type":"integer"},"usage":{"type":"object"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Run the Competitive Landscaping pipeline for an indication or target.","tags":["competitive-landscaping"]}},"/v1/agents/compound-map":{"post":{"description":"Picks a diversified sample of patents mentioning the target, prefers US versions, runs structures-api over each, and returns deduped SMILES with similarity scoring.","operationId":"run_compound_map","requestBody":{"content":{"application/json":{"example":{"max_patents":20,"target":"TROP2"},"schema":{"properties":{"candidate_pool":{"default":200,"type":"integer"},"include_full_clinical_landscape":{"default":true,"description":"Whether FTO may invoke a full Competitive Landscaping run while building the clinical reference landscape. Company-terminal batches set this false because they run Competitive Landscaping separately.","type":"boolean"},"max_crops_per_patent":{"default":12,"type":"integer"},"max_panels_per_patent":{"default":6,"type":"integer"},"max_patents":{"default":20,"type":"integer"},"seed":{"type":"string"},"target":{"description":"Gene/protein symbol, e.g. 'TROP2'.","type":"string"}},"required":["target"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"compound-map","data":{"aliases":["TACSTD2","EGP1"],"assignees":[{"assignee":"Daiichi Sankyo","patent_count":3}],"elapsed_s":311.2,"n_compound_crops":84,"n_selected":20,"n_similarity_pairs":25,"n_smiles_raw":41,"similarity":{"pairs":[{"tanimoto":0.72}]},"target":"TROP2"},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"aliases":{"items":{"type":"string"},"type":"array"},"assignees":{"type":"array"},"elapsed_s":{"type":"number"},"n_compound_crops":{"type":"integer"},"n_selected":{"type":"integer"},"n_similarity_pairs":{"type":"integer"},"n_smiles_raw":{"type":"integer"},"similarity":{"type":"object"},"target":{"type":"string"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Diversified patent sample + SMILES extraction for a target.","tags":["compound-map"]}},"/v1/agents/deal-sourcing":{"post":{"description":"Given an investment thesis, searches the web for private companies, stealth startups, academic spinouts, licensing-ready assets, university papers, ground-breaking research reports, and pre-company signals (labs, grants, patents, PIs). Returns a ranked feed with source-backed mini-memos and suggested next actions.","operationId":"run_deal_sourcing","requestBody":{"content":{"application/json":{"example":{"lookback_days":30,"thesis":"Early-stage oncology platforms with differentiated ADC or bispecific approaches, US/EU based, pre-Series A or stealth with strong academic pedigree."},"schema":{"properties":{"lookback_days":{"default":30,"maximum":30,"minimum":7,"type":"integer"},"thesis":{"description":"Investment thesis describing sector, stage, modality, and deal criteria.","type":"string"},"use_cache":{"default":false,"type":"boolean"}},"required":["thesis"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"deal-sourcing","data":{"deals":[{"deal_score":88,"deal_type":"university_paper","deal_uuid":"550e8400-e29b-41d4-a716-446655440000","entities":{"company":"UCSF lab","geography":"US","modality":"ADC","stage":"Published research"},"memo":"A recent university paper describes a novel linker approach with translational ADC relevance [1][2].","source_ids":["1","2"],"suggested_next_action":{"agent_key":"target_prioritization","text":"Run Target Prioritization to validate targets and genetic evidence behind this ADC approach."},"title":"UCSF linker paper suggests ADC spinout angle"}],"generated_at":"2026-05-27T12:00:00+00:00","sources":[{"date":"2026-05","id":"1","publisher":"PubMed","source_type":"paper","title":"University ADC linker paper","url":"https://pubmed.ncbi.nlm.nih.gov/"},{"date":"2026","id":"2","publisher":"Nature Reviews Drug Discovery","source_type":"research_report","title":"ADC translational report","url":"https://www.nature.com/"}],"thesis":"Early-stage oncology platforms with differentiated ADC approaches\u2026","warnings":[],"week_of":"2026-05-27"},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"deals":{"items":{"type":"object"},"type":"array"},"generated_at":{"type":"string"},"sources":{"items":{"type":"object"},"type":"array"},"thesis":{"type":"string"},"warnings":{"items":{"type":"string"},"type":"array"},"week_of":{"type":"string"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Rank weekly deal opportunities against an investment thesis.","tags":["deal-sourcing"]}},"/v1/agents/differential-expression":{"post":{"description":"Runs differential gene expression analysis from a raw count matrix and sample metadata. Supports DESeq2, edgeR, limma-voom, or all three methods, returning structured DEG tables, method summaries, consensus genes, QC metrics, and warnings.","operationId":"run_differential_expression","requestBody":{"content":{"application/json":{"example":{"comparison_group":"treated","condition_column":"condition","counts_csv":"gene_id,ctrl_1,ctrl_2,trt_1,trt_2\nGeneA,10,12,80,90\nGeneB,100,95,50,48\n","metadata_csv":"sample_id,condition\nctrl_1,control\nctrl_2,control\ntrt_1,treated\ntrt_2,treated\n","method":"all","min_count":10,"reference_group":"control"},"schema":{"properties":{"comparison_group":{"type":"string"},"condition_column":{"type":"string"},"count_file_id":{"description":"Website upload file ID for the count matrix. Use counts_csv for direct API calls.","type":"string"},"counts_csv":{"description":"Inline CSV/TSV count matrix. First column is gene ID unless gene_id_column is set.","type":"string"},"fdr_cutoff":{"default":0.05,"type":"number"},"gene_id_column":{"type":"string"},"log2fc_cutoff":{"default":1.0,"type":"number"},"metadata_csv":{"description":"Inline CSV/TSV sample metadata. First column is sample ID unless sample_id_column is set.","type":"string"},"metadata_file_id":{"description":"Website upload file ID for sample metadata. Use metadata_csv for direct API calls.","type":"string"},"method":{"default":"all","enum":["DESeq2","edgeR","limma-voom","all"],"type":"string"},"min_count":{"default":10,"type":"integer"},"reference_group":{"type":"string"},"sample_id_column":{"type":"string"},"use_cache":{"default":false,"type":"boolean"}},"required":["condition_column","reference_group","comparison_group"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"differential-expression","data":{"consensus":{"genes":["GeneA"],"n_consensus_significant":20,"n_methods":3},"method_results":[{"method":"DESeq2","n_down":17,"n_significant":42,"n_tested":18000,"n_up":25,"table":[],"top_down":[],"top_up":[{"gene_id":"GeneA","log2FC":2.8,"padj":0.001}]}],"sample_qc":{"group_counts":{"control":2,"treated":2},"n_genes_input":20000,"n_genes_numeric":20000,"n_samples_used":4},"summary":{"comparison":"treated vs control","methods_completed":["DESeq2","edgeR","limma-voom"],"significant_by_method":{"DESeq2":42,"edgeR":38,"limma-voom":35}},"warnings":[]},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"consensus":{"type":"object"},"input":{"type":"object"},"method_results":{"items":{"properties":{"method":{"type":"string"},"n_down":{"type":"integer"},"n_significant":{"type":"integer"},"n_tested":{"type":"integer"},"n_up":{"type":"integer"},"table":{"items":{"type":"object"},"type":"array"},"top_down":{"items":{"type":"object"},"type":"array"},"top_up":{"items":{"type":"object"},"type":"array"}},"type":"object"},"type":"array"},"query_id":{"type":"integer"},"run_uuid":{"type":"string"},"sample_qc":{"type":"object"},"status":{"type":"string"},"summary":{"type":"object"},"warnings":{"items":{"type":"string"},"type":"array"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Run RNA-seq differential gene expression analysis with DESeq2, edgeR, and limma-voom.","tags":["differential-expression"]}},"/v1/agents/label-strategy":{"post":{"description":"Builds a structured label strategy report for a drug asset and indication, including likely indication language, label claim opportunities, safety expectations, competitor label comparison, evidence requirements, and risks.","operationId":"run_label_strategy","requestBody":{"content":{"application/json":{"example":{"asset_name":"FW-101","clinical_trial_data":{"CR":"28%","CRS":"55%","Grade3_Infections":"18%","ORR":"62%"},"competitor_assets":["teclistamab","elranatamab","idecabtagene vicleucel"],"development_stage":"Phase 2","endpoints":["ORR","DoR","CR","MRD negativity"],"geography":"FDA","indication":"relapsed/refractory multiple myeloma","mechanism_of_action":"BCMA x CD3 T-cell engagement","modality":"bispecific antibody","target":"BCMA"},"schema":{"properties":{"asset_name":{"description":"Asset or program name.","type":"string"},"biomarker":{"type":"string"},"clinical_trial_data":{"type":"object"},"comparator":{"type":"string"},"competitor_assets":{"items":{"type":"string"},"type":"array"},"development_stage":{"description":"Current development stage.","type":"string"},"dosing_information":{"type":"string"},"endpoints":{"items":{"type":"string"},"type":"array"},"geography":{"description":"Regulatory geography, e.g. FDA, EMA, PMDA.","type":"string"},"indication":{"description":"Target disease and population.","type":"string"},"line_of_therapy":{"type":"string"},"mechanism_of_action":{"description":"Mechanism of action.","type":"string"},"modality":{"description":"Therapeutic modality.","type":"string"},"prior_regulatory_feedback":{"type":"object"},"safety_data":{"type":"object"},"target":{"description":"Molecular or cellular target.","type":"string"},"use_cache":{"default":false,"type":"boolean"}},"required":["asset_name","indication","modality","mechanism_of_action","target","development_stage","geography"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"label-strategy","data":{"executive_summary":{"expected_label_scope":"Adult relapsed or refractory multiple myeloma after multiple prior lines of therapy [1][2].","likely_regulatory_positioning":"Accelerated approval may be plausible if response durability is compelling in a heavily pretreated population [1][2].","major_opportunities":["ORR-based accelerated approval [1]","BCMA-class precedent [1][2]"],"major_risks":["CRS warning likely [1][2]","infection warning likely [1][2]"],"source_ids":["1","2"]},"proposed_indication_language":{"confidence":"Medium","confidence_score":65,"language":"Treatment of adult patients with relapsed or refractory multiple myeloma after at least three prior lines of therapy [1][2].","required_evidence":["clinically meaningful ORR","durable responses","adequate safety database"],"source_ids":["1","2"],"supporting_precedents":["teclistamab","elranatamab"]},"regulatory_risks":[{"mitigation":"Plan confirmatory randomized trial with mature DoR and PFS follow-up.","rationale":"Single-arm Phase 2 data usually support only response-based claims [1][2].","risk":"accelerated approval dependency","severity":"High","source_ids":["1","2"]}],"risk_scores":{"claim_feasibility_score":65,"label_breadth_score":55,"regulatory_risk_score":70,"safety_burden_score":75,"source_ids":["1","2"]},"sources":[{"id":"1","relevance":"BCMA bispecific label precedent","source_type":"FDA label","title":"TECVAYLI prescribing information","url":"https://www.accessdata.fda.gov/"},{"id":"2","relevance":"BCMA bispecific label precedent","source_type":"FDA label","title":"ELREXFIO prescribing information","url":"https://www.accessdata.fda.gov/"}],"warnings":["Generated language is inferred strategy, not approved labeling."]},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"assumptions":{"items":{"type":"string"},"type":"array"},"competitor_label_comparison":{"items":{"type":"object"},"type":"array"},"evidence_to_claim_mapping":{"items":{"type":"object"},"type":"array"},"executive_summary":{"type":"object"},"input":{"type":"object"},"label_scenarios":{"items":{"type":"object"},"type":"array"},"likely_label_restrictions":{"items":{"type":"object"},"type":"array"},"precedents":{"items":{"type":"object"},"type":"array"},"proposed_indication_language":{"type":"object"},"query_id":{"type":"integer"},"recommended_next_steps":{"items":{"type":"string"},"type":"array"},"regulatory_risks":{"items":{"type":"object"},"type":"array"},"risk_scores":{"type":"object"},"run_uuid":{"type":"string"},"safety_warning_expectations":{"type":"object"},"sources":{"items":{"type":"object"},"type":"array"},"status":{"type":"string"},"warnings":{"items":{"type":"string"},"type":"array"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Generate a precedent-backed regulatory label strategy.","tags":["label-strategy"]}},"/v1/agents/new-developments":{"post":{"description":"Scans recent papers, trials, patents, and regulatory events matching user filters, scores each catalyst by signal strength, maps companies and investors, and aggregates results into investor-facing themes with auto-generated briefs.","operationId":"run_new_developments","requestBody":{"content":{"application/json":{"example":{"indication":"solid tumors","lookback_days":60,"modality":"ADC","query":"Show new developments in ADC for solid tumors","stage_focus":"early_clinical","target":"HER2"},"schema":{"properties":{"include_live_discovery":{"default":false,"description":"Supplement demo ingestion with live Scholar/web search.","type":"boolean"},"indication":{"description":"Disease area filter.","type":"string"},"lookback_days":{"default":60,"maximum":365,"minimum":7,"type":"integer"},"modality":{"description":"Modality filter, e.g. ADC, gene therapy.","type":"string"},"query":{"description":"Optional natural-language query, e.g. 'Track GLP-1 alternatives'.","type":"string"},"stage_focus":{"default":"any","enum":["preclinical","early_clinical","late_clinical","regulatory","any"],"type":"string"},"target":{"description":"Target or pathway filter.","type":"string"},"use_cache":{"default":false,"type":"boolean"}},"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"new-developments","data":{"briefs":[{"theme_key":"adc_her2","weekly_brief":"Two new preprint disclosures this week [S1]."}],"catalysts":[{"catalyst_type":"Scientific","entities":{"indication":"solid tumors","modality":"ADC","target":"HER2"},"linked_companies":[{"name":"ExampleBio","stage":"Phase 1"}],"signal_score":82,"summary":"Preclinical data suggest improved stability [S1].","title":"New ADC linker strategy in HER2+ solid tumors"}],"generated_at":"2026-05-26T12:00:00+00:00","themes":[{"catalyst_count":3,"label":"Adc Her2","summary":"HER2 ADC space showing renewed linker innovation [S1].","theme_key":"adc_her2"}]},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"briefs":{"items":{"type":"object"},"type":"array"},"catalysts":{"items":{"type":"object"},"type":"array"},"filters":{"type":"object"},"generated_at":{"type":"string"},"sources":{"items":{"type":"object"},"type":"array"},"themes":{"items":{"type":"object"},"type":"array"},"warnings":{"items":{"type":"string"},"type":"array"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Identify and rank emerging biopharma catalysts for deal sourcing.","tags":["new-developments"]}},"/v1/agents/patent-mining":{"post":{"description":"Programmatic access to the /patents tool. Use ``subagent`` to select Patent Landscape, Markush Extract, or Structure Similarity.","operationId":"run_patent_mining","requestBody":{"content":{"application/json":{"example":{"drug_name":"trastuzumab","subagent":"patent_landscape"},"schema":{"properties":{"drug_name":{"description":"Required for patent_landscape, e.g. 'trastuzumab'.","type":"string"},"max_candidates":{"default":300,"type":"integer"},"min_similarity":{"default":0.3,"type":"number"},"patent_id":{"description":"Required for markush_extract, e.g. 'US10123456B2'.","type":"string"},"query_smiles":{"description":"Required for structure_similarity.","type":"string"},"sub_modality":{"default":"conventional","enum":["conventional","covalent","protac","glue","macrocycle"],"type":"string"},"subagent":{"description":"Which /patents mode to run.","enum":["patent_landscape","markush_extract","structure_similarity"],"type":"string"},"target":{"description":"Required for structure_similarity, e.g. 'EGFR'.","type":"string"}},"required":["subagent"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"patent-mining","data":{"result":{"drug":{"alt_names":["Herceptin"],"company":"Genentech / Roche","licensor":"","licensor_acquirer":"","modality_type":"antibody","name":"trastuzumab","target":"HER2"},"n_patents":54,"patents":[{"assignee":"Genentech","claim_basis":"composition claims","claim_type":"composition","classification":"CORE MOLECULE PATENT","classification_confidence":"high","family_id":"12345678","family_tree":null,"filing_date":"2006-08-25","jurisdiction":"US","link":"https://patents.google.com/patent/US8211429B2/en","match_type":"direct","patent_id":"US-8211429-B2","priority_date":"2005-08-25","publication_date":"2012-07-03","relevance":"direct","score":92,"secondary_type":"","summary":"Covers anti-HER2 antibody treatment claims.","title":"Treatment with anti-ErbB2 antibodies","triage":"keep"}],"query_id":12345,"run_id":"drugrun_1715731200_trastuzumab"},"subagent":"patent_landscape","summary":"54 patents for trastuzumab"},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"result":{"description":"Native result from the selected subagent. For patent_landscape: {drug, patents, n_patents, run_id, query_id}.","type":"object"},"subagent":{"type":"string"},"summary":{"type":"string"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Run one of the Patent Mining modes: landscape, Markush, or similarity.","tags":["patent-mining"]}},"/v1/agents/patent-structures":{"post":{"description":"Submits a patent number to the structures-api service which scrapes Google Patents images, splits compound panels, and runs DECIMER + chemical-structure cleanup to recover SMILES.","operationId":"run_patent_structures","requestBody":{"content":{"application/json":{"example":{"patent_number":"US-11242388-B2"},"schema":{"properties":{"include_drawings":{"default":false,"type":"boolean"},"patent_number":{"description":"Publication number, e.g. 'US-11242388-B2'.","type":"string"}},"required":["patent_number"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"patent-structures","data":{"assignee":"Daiichi Sankyo","google_patents_url":"https://patents.google.com/patent/US11242388B2","images":[{"section":"Compound 1","url":"https://...panel.png"}],"patent_number":"US-11242388-B2","title":"TROP2 antibody-drug conjugate"},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"assignee":{"type":"string"},"google_patents_url":{"type":"string"},"images":{"items":{"properties":{"section":{"type":"string"},"url":{"type":"string"}},"type":"object"},"type":"array"},"patent_number":{"type":"string"},"resolved_patent_id":{"type":"string"},"title":{"type":"string"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Extract chemical structure panels (and SMILES) from a patent.","tags":["patent-structures"]}},"/v1/agents/platform-analysis":{"post":{"description":"Analyzes a biotech platform and its competitive landscape from a VC diligence perspective. Given a query (and optional uploaded files such as decks, papers, or patents), it identifies the target company, maps platform claims to evidence, finds direct and adjacent competitors, builds a comparable company set, and surfaces key risks and diligence questions.","operationId":"run_platform_analysis","requestBody":{"content":{"application/json":{"example":{"query":"Platform competitive landscaping for CatenaBio's CysTyr/Catenase platform."},"schema":{"properties":{"query":{"description":"Free-form description of the platform to analyze. Example: 'Do platform competitive landscaping for CatenaBio\\'s CysTyr/Catenase platform.'","type":"string"},"uploaded_files":{"description":"File IDs returned by POST /api/platform_analysis/files. Accepted formats: PDF, TXT, MD, DOCX, XLSX, CSV, JSON.","items":{"type":"string"},"type":"array"},"use_cache":{"default":false,"description":"Return the most recent completed run for the same query instead of re-running.","type":"boolean"}},"required":["query"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"platform-analysis","data":{"bottom_line":{"biggest_competitive_risk":"Genentech/Roche THIOMAB is entrenched; pharma may prefer incumbent.","evidence_to_improve_conviction":"Preclinical PK/PD data head-to-head vs THIOMAB; partner deal.","is_real_platform":"Early-stage platform with credible chemistry but no clinical validation yet.","strongest_differentiation":"Dual cysteine-tyrosine chemistry expands conjugation site repertoire."},"direct_competitors":[{"company":"Genentech/Roche","differentiation_vs_target":"CatenaBio adds tyrosine residue flexibility; THIOMAB is cysteine-only","platform":"THIOMAB site-specific conjugation","status":"Established, multiple clinical programs","threat_level":"High","why_relevant":"Earliest cysteine-based site-specific ADC platform; set industry benchmark"}],"executive_summary":"CatenaBio's Catenase platform uses engineered cysteine-tyrosine chemistry to enable site-specific ADC conjugation with homogeneous DAR. The platform competes directly with THIOMAB (Genentech/Roche), maleimide-free rebridging approaches (Polytherics/Abzena), and transglutaminase conjugation (Ajinomoto). Key differentiation is dual-residue flexibility, but clinical validation is absent.","generated_at":"2026-05-23T00:00:00+00:00","sources":[{"date":"2023","id":"S1","publisher":"Genentech","title":"THIOMAB Platform Overview","url":"https://example.com"}],"warnings":[]},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"adjacent_competitors":{"items":{"type":"object"},"type":"array"},"bottom_line":{"type":"object"},"comparable_companies":{"items":{"type":"object"},"type":"array"},"competitive_taxonomy":{"type":"object"},"differentiation_matrix":{"items":{"type":"object"},"type":"array"},"diligence_questions":{"items":{"type":"object"},"type":"array"},"direct_competitors":{"items":{"type":"object"},"type":"array"},"executive_summary":{"type":"string"},"generated_at":{"type":"string"},"key_risks":{"items":{"type":"object"},"type":"array"},"maturity_matrix":{"items":{"type":"object"},"type":"array"},"platform_claim_map":{"items":{"type":"object"},"type":"array"},"sources":{"items":{"type":"object"},"type":"array"},"target_platform_overview":{"type":"object"},"warnings":{"items":{"type":"string"},"type":"array"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"VC-style competitive landscape for a biotech platform.","tags":["platform-analysis"]}},"/v1/agents/target-prioritization":{"post":{"description":"Runs the Target Prioritization pipeline for a (target, indication) pair. Returns the structured results_json containing per-evaluator scores and the overall suitability.","operationId":"run_target_prioritization","requestBody":{"content":{"application/json":{"example":{"indication":"NSCLC","target":"TROP2"},"schema":{"properties":{"indication":{"description":"Tumor / disease, e.g. 'NSCLC'.","type":"string"},"phases":{"description":"Optional subset of evaluators to run; default = all 8.","items":{"type":"string"},"type":"array"},"target":{"description":"Gene/protein symbol, e.g. 'TROP2'.","type":"string"},"use_cache":{"default":false,"description":"If a prior completed run exists for this target+indication, reuse it.","type":"boolean"}},"required":["target"],"type":"object"}}},"required":true},"responses":{"200":{"content":{"application/json":{"example":{"agent":"target-prioritization","data":{"evaluators":{"ecd":{"notes":"...","score":0.91},"expression":{"notes":"...","score":0.82}},"indication":"NSCLC","overall_score":0.78,"query_id":9422,"run_uuid":"f1a4...","target":"TROP2"},"elapsed_s":42.0,"ok":true,"run_id":"abc123"},"schema":{"properties":{"agent":{"type":"string"},"data":{"properties":{"evaluators":{"type":"object"},"indication":{"type":"string"},"overall_score":{"type":"number"},"query_id":{"type":"integer"},"run_uuid":{"type":"string"},"target":{"type":"string"}},"type":"object"},"elapsed_s":{"type":"number"},"ok":{"type":"boolean"},"run_id":{"type":"string"}},"type":"object"}}},"description":"Agent run completed"},"400":{"description":"Invalid input"},"401":{"description":"Missing or invalid API key"},"402":{"description":"Quota exceeded"},"500":{"description":"Agent failed"},"504":{"description":"Agent timed out"}},"security":[{"BearerAuth":[]}],"summary":"Score a target across 8 evaluators (expression, ECD, druggability, ...).","tags":["target-prioritization"]}}},"servers":[{"description":"Production","url":"https://api.frontwind.ai"},{"description":"Cloud Run direct","url":"https://notebook-app-xflr6kvnra-uc.a.run.app"}]}